Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344692 | 0.84 | TPSAB1 (0.61) | HTTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL17335992 | 0.84 | CYP3A4 (0.63) | ALDH1A1TDP1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL93948 | 0.83 | GAA (0.75) | HTTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL16205823 | 0.82 | HTT (0.70) | HTTALDH1A1KMT2AMEN1TPSAB1 | |
| SCHEMBL14679156 | 0.82 | TPSAB1 (0.62) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL11887809 | 0.82 | HTT (0.70) | HTTALDH1A1KMT2AMEN1TPSAB1 | |
| SCHEMBL21887672 | 0.82 | TPSAB1 (0.86) | HTTALDH1A1KMT2AMEN1TPSAB1 | |
| SCHEMBL2453831 | 0.82 | HTT (0.70) | HTTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL27892112 | 0.82 | HTT (1.00) | HTTALDH1A1KMT2AHPGDTPSAB1 | |
| SCHEMBL25046063 | 0.81 | ALDH1A1 (0.71) | HTTALDH1A1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362199-B2 | Borazine-based resin, process for its production, borazine-based resin composition, insulating film and method for its formation | HITACHI CHEMICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20110313122-A1 | BORAZINE-BASED RESIN, PROCESS FOR ITS PRODUCTION, BORAZINE-BASED RESIN COMPOSITION, INSULATING FILM AND METHOD FOR ITS FORMATION | MATSUTANI HIROSHI (JP) | 2011-12-22 | — | — | US | disclosed |
| US-7625642-B2 | Borazine-based resin, and method for production thereof, borazine based resin composition, insulating coating and method for formation thereof, and electronic parts having the insulating coating | HITACHI CHEMICAL CO., LTD (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20090240017-A1 | Borazine-based resin, process for its production, borazine-based resin composition, insulating film and method for its formation | HITACHI CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| WO-2007142431-A1 | NEW NON-PEPTIDE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2007-12-13 | — | — | WO | disclosed |
| EP-0461677-B1 | Novel thiazolidine derivatives | ONO PHARMACEUTICAL CO (JP) | 1997-04-16 | — | — | EP | disclosed |
| EP-0280956-B1 | THIAZOLIDINE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| EP-0461677-A1 | Novel thiazolidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4857537-A | PREVENTING AMNESIA | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0280956-A1 | Thiazolidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313122-A1 | BORAZINE-BASED RESIN, PROCESS FOR ITS PRODUCTION, BORAZINE-BASED RESIN COMPOSITION, INSULATING FILM AND METHOD FOR ITS FORMATION | GRIK5, GJA1, SLC9A5 | HTT 3590/4885ALDH1A1 2955/4885TDP1 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.